Logo image of ONCO

ONCONETIX INC (ONCO) Stock Fundamental Analysis

NASDAQ:ONCO - Nasdaq - US68237Q1040 - Common Stock - Currency: USD

0.0595  0 (-0.17%)

After market: 0.0572 0 (-3.87%)

Fundamental Rating

0

ONCO gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. ONCO has a bad profitability rating. Also its financial health evaluation is rather negative. ONCO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ONCO had negative earnings in the past year.
In the past year ONCO has reported a negative cash flow from operations.
In the past 5 years ONCO always reported negative net income.
In the past 5 years ONCO always reported negative operating cash flow.
ONCO Yearly Net Income VS EBIT VS OCF VS FCFONCO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -83.34%, ONCO is doing worse than 70.77% of the companies in the same industry.
ONCO has a Return On Equity of -152.17%. This is in the lower half of the industry: ONCO underperforms 63.73% of its industry peers.
Industry RankSector Rank
ROA -83.34%
ROE -152.17%
ROIC N/A
ROA(3y)-75.1%
ROA(5y)-57.66%
ROE(3y)-134.27%
ROE(5y)-93.36%
ROIC(3y)N/A
ROIC(5y)N/A
ONCO Yearly ROA, ROE, ROICONCO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

ONCO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONCO Yearly Profit, Operating, Gross MarginsONCO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -20K -40K -60K

More info and screens

1

2. Health

2.1 Basic Checks

ONCO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ONCO has less shares outstanding
ONCO has a worse debt/assets ratio than last year.
ONCO Yearly Shares OutstandingONCO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M
ONCO Yearly Total Debt VS Total AssetsONCO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -3.05, we must say that ONCO is in the distress zone and has some risk of bankruptcy.
ONCO has a Altman-Z score (-3.05) which is comparable to the rest of the industry.
ONCO has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
ONCO's Debt to Equity ratio of 0.29 is on the low side compared to the rest of the industry. ONCO is outperformed by 70.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Altman-Z -3.05
ROIC/WACCN/A
WACC5.76%
ONCO Yearly LT Debt VS Equity VS FCFONCO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M 40M

2.3 Liquidity

ONCO has a Current Ratio of 0.06. This is a bad value and indicates that ONCO is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.06, ONCO is doing worse than 97.71% of the companies in the same industry.
A Quick Ratio of 0.05 indicates that ONCO may have some problems paying its short term obligations.
ONCO has a Quick ratio of 0.05. This is amonst the worse of the industry: ONCO underperforms 97.89% of its industry peers.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.05
ONCO Yearly Current Assets VS Current LiabilitesONCO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ONCO have decreased strongly by -8438.24% in the last year.
EPS 1Y (TTM)-8438.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-845.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -14.13% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.84%
EPS Next 2Y-14.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONCO Yearly Revenue VS EstimatesONCO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 10K 20K 30K 40K 50K
ONCO Yearly EPS VS EstimatesONCO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ONCO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ONCO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONCO Price Earnings VS Forward Price EarningsONCO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONCO Per share dataONCO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

A cheap valuation may be justified as ONCO's earnings are expected to decrease with -14.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.13%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ONCO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCONETIX INC

NASDAQ:ONCO (4/17/2025, 8:00:02 PM)

After market: 0.0572 0 (-3.87%)

0.0595

0 (-0.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2024-05-12
Earnings (Next)N/A N/A
Inst Owners2.85%
Inst Owner Change0%
Ins Owners8.99%
Ins Owner Change0.04%
Market Cap865.73K
Analysts43.33
Price TargetN/A
Short Float %2.23%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.46
P/FCF N/A
P/OCF N/A
P/B 0.03
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-95.63
EYN/A
EPS(NY)-1.01
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.95
OCFYN/A
SpS0.13
BVpS2.33
TBVpS-1.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -83.34%
ROE -152.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.1%
ROA(5y)-57.66%
ROE(3y)-134.27%
ROE(5y)-93.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.48%
Cap/Sales 1.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.05
Altman-Z -3.05
F-Score3
WACC5.76%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8438.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-845.26%
EPS Next Y-11.84%
EPS Next 2Y-14.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-111.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-111.4%
OCF growth 3YN/A
OCF growth 5YN/A